Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell NewsScientists reported results from a phase I/II clinical trial in which six metastatic HLA-A2 melanoma patients received autologous antigen-specific T-cells produced from peripheral blood mononuclear cells, after peptide stimulation in vitro, followed by sorting with HLA-peptide multimers and amplification.
[Cancer Immunology Immunotherapy]
7753456 {7753456:BRDWQCQJ} apa 50 1 163380 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-ef011abf810bfd332a4b1a08e15840e1%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22BRDWQCQJ%22%2C%22library%22%3A%7B%22id%22%3A7753456%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dr%5Cu00e9no%20et%20al.%22%2C%22parsedDate%22%3A%222021-06-12%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%202%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDr%26%23xE9%3Bno%2C%20B.%2C%20Khammari%2C%20A.%2C%20Fortun%2C%20A.%2C%20Vignard%2C%20V.%2C%20Saiagh%2C%20S.%2C%20Beauvais%2C%20T.%2C%20Jouand%2C%20N.%2C%20Bercegay%2C%20S.%2C%20Simon%2C%20S.%2C%20Lang%2C%20F.%2C%20%26amp%3B%20Labarri%26%23xE8%3Bre%2C%20N.%20%282021%29.%20Phase%20I%5C%2FII%20clinical%20trial%20of%20adoptive%20cell%20transfer%20of%20sorted%20specific%20T%20cells%20for%20metastatic%20melanoma%20patients.%20%3Ci%3ECancer%20Immunology%2C%20Immunotherapy%3C%5C%2Fi%3E.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00262-021-02961-0%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00262-021-02961-0%3C%5C%2Fa%3E%20%3Ca%20title%3D%27Cite%20in%20RIS%20Format%27%20class%3D%27zp-CiteRIS%27%20href%3D%27https%3A%5C%2F%5C%2Fwww.stemcellsciencenews.com%5C%2Fwp-content%5C%2Fplugins%5C%2Fzotpress%5C%2Flib%5C%2Frequest%5C%2Frequest.cite.php%3Fapi_user_id%3D7753456%26amp%3Bitem_key%3DBRDWQCQJ%27%3ECite%3C%5C%2Fa%3E%20%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phase%20I%5C%2FII%20clinical%20trial%20of%20adoptive%20cell%20transfer%20of%20sorted%20specific%20T%20cells%20for%20metastatic%20melanoma%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Dr%5Cu00e9no%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amir%22%2C%22lastName%22%3A%22Khammari%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Fortun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Vignard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Soraya%22%2C%22lastName%22%3A%22Saiagh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tiffany%22%2C%22lastName%22%3A%22Beauvais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Jouand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Bercegay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Lang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Labarri%5Cu00e8re%22%7D%5D%2C%22abstractNote%22%3A%22Adoptive%20cell%20transfer%20%28ACT%29%20of%20tumor-specific%20T%20lymphocytes%20represents%20a%20relevant%20therapeutic%20strategy%20to%20treat%20metastatic%20melanoma%20patients.%20Ideal%20T-cells%20should%20combine%20tumor%20specificity%20and%20reactivity%20with%20survival%20in%20vivo%2C%20while%20avoiding%20autoimmune%20side%20effects.%20Here%20we%20report%20results%20from%20a%20Phase%20I%5C%2FII%20clinical%20trial%20%28NCT02424916%2C%20performed%20between%202015%20and%202018%29%20in%20which%206%20metastatic%20HLA-A2%20melanoma%20patients%20received%20autologous%20antigen-specific%20T-cells%20produced%20from%20PBMC%2C%20after%20peptide%20stimulation%20in%20vitro%2C%20followed%20by%20sorting%20with%20HLA-peptide%20multimers%20and%20amplification.%20Each%20patient%20received%20a%20combination%20of%20Melan-A%20and%20MELOE-1%20polyclonal%20specific%20T-cells%2C%20whose%20specificity%20and%20anti-tumor%20reactivity%20were%20checked%20prior%20to%20injection%2C%20with%20subcutaneous%20IL-2.%20Transferred%20T-cells%20were%20also%20characterized%20in%20terms%20of%20functional%20avidity%2C%20diversity%20and%20phenotype%20and%20their%20blood%20persistence%20was%20evaluated.%20An%20increase%20in%20specific%20T-cells%20was%20detected%20in%20the%20blood%20of%20all%20patients%20at%20day%201%20and%20progressively%20disappeared%20from%20day%207%20onwards.%20No%20serious%20adverse%20events%20occurred%20after%20this%20ACT.%20Clinically%2C%20five%20patients%20progressed%20and%20one%20patient%20experienced%20a%20partial%20response%20following%20therapy.%20Melan-A%20and%20MELOE-1%20specific%20T-cells%20infused%20to%20this%20patient%20were%20diverse%2C%20of%20high%20avidity%2C%20with%20a%20high%20proportion%20of%20T%20lymphocytes%20co-expressing%20PD-1%20and%20TIGIT%20but%20few%20other%20exhaustion%20markers.%20In%20conclusion%2C%20we%20demonstrated%20the%20feasibility%20and%20safety%20of%20ACT%20with%20multimer-sorted%20Melan-A%20and%20MELOE-1%20specific%20T%20cells%20to%20metastatic%20melanoma%20patients.%20The%20clinical%20efficacy%20of%20such%20therapeutic%20strategy%20could%20be%20further%20enhanced%20by%20the%20selection%20of%20highly%20reactive%20T-cells%2C%20based%20on%20PD-1%20and%20TIGIT%20co-expression%2C%20and%20a%20combination%20with%20ICI%2C%20such%20as%20anti-PD-1.%22%2C%22date%22%3A%222021-06-12%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00262-021-02961-0%22%2C%22ISSN%22%3A%221432-0851%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00262-021-02961-0%22%2C%22deleted%22%3A1%2C%22collections%22%3A%5B%22DUPVZUHA%22%5D%2C%22dateModified%22%3A%222021-06-14T17%3A44%3A47Z%22%7D%7D%5D%7D
Dréno, B., Khammari, A., Fortun, A., Vignard, V., Saiagh, S., Beauvais, T., Jouand, N., Bercegay, S., Simon, S., Lang, F., & Labarrière, N. (2021). Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-021-02961-0 Cite
